AstraZeneca and Daiichi Sankyo have announced that their supplemental Biologics License Application (sBLA) for Enhertu ...

Pharma R&D faces rising trial complexity, high costs, and patient and investigator shortages, driving the need for adaptive models and data-driven strategies to speed therapies to market.

AI also improves the negotiation process by surfacing fallback clauses and highlighting site-specific preferences. If an institution like Mass General or MSK insists on certain language, the system ...

In this video interview, Ananth Kadambi, VP of real-world evidence and modeling solutions at Certara, explains how integrating real-world evidence and predictive modeling early in development can ...

Modernizing Clinical Trials: A Site-Centered Roadmap for the Future Simplifying startup, empowering sites through networks, ...

Michel van Harten, MD, CEO, myTomorrows; and Kyle McAllister, co-founder, CEO, Trially, discuss how artificial intelligence ...

Clinical trials frequently struggle with challenges due to slow enrollment, poor patient retention and operational delays, which can result in rescue studies. Learn how Quest Diagnostics and ...

The pharmaceutical industry, with its wealth of sensitive data and critical research, must remain at the forefront of cybersecurity efforts. By integrating cybersecurity considerations into every ...

Tom Cowen, head, healthcare, life sciences, Conga, explains why investigator onboarding creates significant delays in clinical trials and how smarter contract management can help sponsors accelerate ...

In this video interview, Ananth Kadambi, VP of real-world evidence and modeling solutions at Certara, discusses how model-informed drug development can help sponsors predict efficacy and safety ...

In this video interview, Ananth Kadambi, VP of real-world evidence and modeling solutions at Certara, outlines how FDA’s ...

An interim analysis of the TULIP-SC trial found that weekly subcutaneous delivery of Saphnelo significantly reduced disease ...